Collegium Pharmaceutical, Inc. P/E Ratio 2013–2025
Collegium Pharmaceutical, Inc. reported 26.76 of price-to-earnings ratio for fiscal 2025. That was 73.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +1.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 26.76 | +73.7% |
| FY 2024 | 15.40 | -35.4% |
| FY 2023 | 23.86 | — |
| FY 2022 | — | — |
| FY 2021 | 10.04 | -61.9% |
| FY 2020 | 26.36 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
Source: Collegium Pharmaceutical, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open COLL 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Collegium Pharmaceutical, Inc. reported 26.76 of price-to-earnings ratio for fiscal 2025. That was 73.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +1.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Collegium Pharmaceutical, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCollegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s price-to-earnings ratio?
Collegium Pharmaceutical, Inc. (COLL) reported price-to-earnings ratio of 26.76 for fiscal year 2025, per its SEC filings.
How has Collegium Pharmaceutical, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2013 and 2025, COLL's price-to-earnings ratio grew at roughly 0.1% per year (compound annual rate), from 26.36 to 26.76.
Where does this data come from?
Figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More COLL financial history
Full COLL fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →